
TY  - JOUR
TI  - TSANZ Abstracts
JO  - Respirology
VL  - 10
IS  - s1
SN  - 1323-7799
UR  - https://doi.org/10.1111/j.1440-1843.2005.00663.x-i1
DO  - doi:10.1111/j.1440-1843.2005.00663.x-i1
SP  - A8
EP  - A94
PY  - 2005
ER  - 

TY  - JOUR
TI  - Others
JO  - Journal of the European Academy of Dermatology and Venereology
VL  - 24
IS  - s4
SN  - 0926-9959
UR  - https://doi.org/10.1111/j.1468-3083.2010.03718_15.x
DO  - doi:10.1111/j.1468-3083.2010.03718_15.x
SP  - 75
EP  - 83
PY  - 2010
ER  - 

TY  - JOUR
AU  - Bangash, Mansoor N
AU  - Kong, Ming-Li
AU  - Pearse, Rupert M
TI  - Use of inotropes and vasopressor agents in critically ill patients
JO  - British Journal of Pharmacology
VL  - 165
IS  - 7
SN  - 0007-1188
UR  - https://doi.org/10.1111/j.1476-5381.2011.01588.x
DO  - doi:10.1111/j.1476-5381.2011.01588.x
SP  - 2015
EP  - 2033
KW  - inotrope
KW  - vasopressor
KW  - critical illness
KW  - haemodynamic shock
PY  - 2012
AB  - Inotropes and vasopressors are biologically and clinically important compounds that originate from different pharmacological groups and act at some of the most fundamental receptor and signal transduction systems in the body. More than 20 such agents are in common clinical use, yet few reviews of their pharmacology exist outside of physiology and pharmacology textbooks. Despite widespread use in critically ill patients, understanding of the clinical effects of these drugs in pathological states is poor. The purpose of this article is to describe the pharmacology and clinical applications of inotropic and vasopressor agents in critically ill patients. LINKED ARTICLES This article is commented on by Bracht et?al., pp. 2009?2011 and De Backer and Scolletta, pp. 2012?2014 of this issue. To view Bracht et?al. visit http://dx.doi.org/10.1111/j.1476-5381.2011.01776.x and to view De Backer and Scolletta visit http://dx.doi.org/10.1111/j.1476-5381.2011.01746.x
ER  - 

TY  - JOUR
TI  - 21st Annual Meeting of the Wound Healing Society SAWC-Spring/WHS Joint Meeting
JO  - Wound Repair and Regeneration
VL  - 19
IS  - 2
SN  - 1067-1927
UR  - https://doi.org/10.1111/j.1524-475X.2010.00670.x
DO  - doi:10.1111/j.1524-475X.2010.00670.x
SP  - A8
EP  - A62
PY  - 2011
ER  - 

TY  - JOUR
TI  - Administrative Operations
JO  - Transfusion
VL  - 46
IS  - 9s
SN  - 0041-1132
UR  - https://doi.org/10.1111/j.1537-2995.2006.01023_2.x
DO  - doi:10.1111/j.1537-2995.2006.01023_2.x
SP  - 165A
EP  - 233A
PY  - 2006
ER  - 

AU  - Bradley, David S.
C7  - pp. 100-113
TI  - Wounds
SN  - 9781119220114
UR  - https://doi.org/10.1002/9781119220190.ch10
DO  - doi:10.1002/9781119220190.ch10
SP  - 100-113
KW  - wounds
KW  - laser therapy
KW  - photobiomodulation
KW  - optimal
KW  - parameters
KW  - contaminated
KW  - infected
KW  - incision
KW  - lick granuloma
KW  - burns
PY  - 2006
AB  - Summary The use of laser therapy for wound healing has been one of the most studied and implemented applications of photobiomodulation. The established mechanisms and physiologic benefits behind laser therapy make it an obvious choice as an adjunct modality to improve the speed and quality of wound repair. Acute and chronic, mild and severe, and clean and contaminated wounds of all species will respond favorably to laser therapy. For the best clinical results, we need to understand and be able to modify available laser parameters to deliver optimal photobiomodulation treatment regimes.
ER  - 

TY  - JOUR
TI  - Poster Section 7: One Health and Translational Medicine
JO  - Journal of Veterinary Pharmacology and Therapeutics
JA  - J vet Pharmacol Therap
VL  - 41
IS  - S1
SN  - 9781119220114
UR  - https://doi.org/10.1111/jvp.12662
DO  - doi:10.1111/jvp.12662
SP  - 111
EP  - 113
PY  - 2018
ER  - 

TY  - JOUR
AU  - Liu, Chih-Wei
AU  - Atkinson, Mark A.
AU  - Zhang, Qibin
TI  - Type 1 diabetes cadaveric human pancreata exhibit a unique exocrine tissue proteomic profile
JO  - PROTEOMICS
JA  - Proteomics
VL  - 16
IS  - 9
SN  - 9781119220114
UR  - https://doi.org/10.1002/pmic.201500333
DO  - doi:10.1002/pmic.201500333
SP  - 1432
EP  - 1446
KW  - Biomedicine
KW  - Isobaric labeling
KW  - nPOD
KW  - Pancreas proteome
KW  - TMT10
KW  - Type 1 diabetes
PY  - 2016
AB  - Type 1 diabetes (T1D) is an autoimmune disorder resulting from a self-destruction of pancreatic islet beta cells. The complete proteome of the human pancreas, where both the dysfunctional beta cells and their proximal environment co-exist, remains unknown. Here, we used TMT10-based isobaric labeling and multidimensional LC-MS/MS to quantitatively profile the differences between pancreatic head region tissues from T1D (N = 5) and healthy subjects (N = 5). Among the 5357 (1% false discovery rate) confidently identified proteins, 145 showed statistically significant dysregulation between T1D and healthy subjects. The differentially expressed pancreatic proteome supports the growing notion of a potential role for exocrine pancreas involvement in T1D. This study also demonstrates the utility for this approach to analyze dysregulated proteins as a means to investigate islet biology, pancreatic pathology and T1D pathogenesis.
ER  - 

TY  - JOUR
TI  - Abstract of the 35th international congress of the ISBT
JO  - Vox Sanguinis
JA  - Vox Sang
VL  - 113
IS  - S1
SN  - 9781119220114
UR  - https://doi.org/10.1111/vox.12658
DO  - doi:10.1111/vox.12658
SP  - 5
EP  - 347
PY  - 2018
ER  - 

TY  - JOUR
TI  - Monday 4th April 2011 Free Communications: Haemostasis and Thrombosis
JO  - British Journal of Haematology
VL  - 153
IS  - s1
SN  - 9781119220114
UR  - https://doi.org/10.1111/j.1365-2141.2011.08609.x
DO  - doi:10.1111/j.1365-2141.2011.08609.x
SP  - 1
EP  - 88
PY  - 2011
ER  - 

TY  - JOUR
TI  - Abstracts–Symposia
JO  - Alcoholism: Clinical and Experimental Research
JA  - Alcohol Clin Exp Res
VL  - 37
IS  - s2
SN  - 9781119220114
UR  - https://doi.org/10.1111/acer.12163
DO  - doi:10.1111/acer.12163
SP  - 254A
EP  - 308A
PY  - 2013
ER  - 

TY  - JOUR
TI  - Poster Session Abstracts
JO  - Pediatric Pulmonology
JA  - Pediatr Pulmonol.
VL  - 50
IS  - S41
SN  - 9781119220114
UR  - https://doi.org/10.1002/ppul.23297
DO  - doi:10.1002/ppul.23297
SP  - S193
EP  - S453
PY  - 2015
ER  - 

TY  - JOUR
AU  - Mayet, Naeema
AU  - Choonara, Yahya E.
AU  - Kumar, Pradeep
AU  - Tomar, Lomas K.
AU  - Tyagi, Charu
AU  - Du Toit, Lisa C.
AU  - Pillay, Viness
TI  - A Comprehensive Review of Advanced Biopolymeric Wound Healing Systems
JO  - Journal of Pharmaceutical Sciences
JA  - J. Pharm. Sci.
VL  - 103
IS  - 8
SN  - 9781119220114
UR  - https://doi.org/10.1002/jps.24068
DO  - doi:10.1002/jps.24068
SP  - 2211
EP  - 2230
KW  - wound healing
KW  - skin
KW  - wound dressings
KW  - bioactive agents
KW  - nanotechnology
KW  - extracellular matrix (ECM)
KW  - polymeric biomaterials
KW  - tissue engineering
KW  - hydrogels
PY  - 2014
AB  - Wound healing is a complex and dynamic process that involves the mediation of many initiators effective during the healing process such as cytokines, macrophages and fibroblasts. In addition, the defence mechanism of the body undergoes a step-by-step but continuous process known as the wound healing cascade to ensure optimal healing. Thus, when designing a wound healing system or dressing, it is pivotal that key factors such as optimal gaseous exchange, a moist wound environment, prevention of microbial activity and absorption of exudates are considered. A variety of wound dressings are available, however, not all meet the specific requirements of an ideal wound healing system to consider every aspect within the wound healing cascade. Recent research has focussed on the development of smart polymeric materials. Combining biopolymers that are crucial for wound healing may provide opportunities to synthesise matrices that are inductive to cells and that stimulate and trigger target cell responses crucial to the wound healing process. This review therefore outlines the processes involved in skin regeneration, optimal management and care required for wound treatment. It also assimilates, explores and discusses wound healing drug-delivery systems and nanotechnologies utilised for enhanced wound healing applications. ? 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:2211?2230, 2014
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Journal of Thrombosis and Haemostasis
VL  - 3
IS  - s1
SN  - 9781119220114
UR  - https://doi.org/10.1111/j.1538-7836.2005.03000.x
DO  - doi:10.1111/j.1538-7836.2005.03000.x
SP  - H01
EP  - SYM90
PY  - 2005
ER  - 

TY  - JOUR
TI  - Podium Presentations
JO  - BJU International
JA  - BJU Int
VL  - 121
IS  - S1
SN  - 9781119220114
UR  - https://doi.org/10.1111/bju.14116
DO  - doi:10.1111/bju.14116
SP  - 4
EP  - 34
PY  - 2018
ER  - 

TY  - JOUR
AU  - Kelly, Robert I
TI  - Cutaneous vasculitis and cutaneous vasculopathies
JO  - Australasian Journal of Dermatology
VL  - 36
IS  - 3
SN  - 9781119220114
UR  - https://doi.org/10.1111/j.1440-0960.1995.tb00952.x
DO  - doi:10.1111/j.1440-0960.1995.tb00952.x
SP  - 109
EP  - 119
KW  - antiphospholipid antibodies
KW  - cryoglobulinaemic vasculitis
KW  - granulomatous vasculitis
KW  - Henoch-Schönlein purpura
KW  - leukocytoclastic vasculitis
KW  - livedo vasculitis
KW  - microscopic polyarteritis
KW  - polyarteritis nodosa
KW  - pustular vasculitis
KW  - urticarial vasculitis
PY  - 1995
AB  - SUMMARY Cutaneous involvement may occur with virtually all syndromes of vasculitis. This can occur primarily as a dermatologic disorder or as a manifestation of a potentially life threatening systemic vasculitis. In this review article, classification, clinical manifestations, pathogenesis and therapy of cutaneous vasculitis will be discussed. Disorders which are primarily vascular in origin but lack a well defined inflammatory phase, referred to as ?vasculopathies? will also be discussed.
ER  - 

AU  - Baldwin III, William M.
AU  - Fairchild, Robert L.
C7  - pp. 60-67
TI  - Humoral Mechanisms of Adaptive Immunity
SN  - 9781118870143
UR  - https://doi.org/10.1002/9781118873434.ch6
DO  - doi:10.1002/9781118873434.ch6
SP  - 60-67
KW  - basic (laboratory)research/science
KW  - cellular biology
KW  - immunobiology
KW  - accommodation
KW  - alloantibody
KW  - antibody biology
KW  - B cell biology
KW  - complement biology
KW  - plasma cells
KW  - vascular biology
PY  - 1995
AB  - Summary Antibodies can cause hyperacute, acute, or chronic rejection of allografts. These different types of rejection involve additional humoral mediators, including complement, coagulation factors, and cytokines, which engage cells of the innate immune system, notably platelets, granulocytes, and monocyte/macrophages. In this chapter we discuss the functional properties of antibodies that influence which humoral and cellular mediators are activated. Then the effects of complement activation and regulation are considered. The mechanisms by which antibodies and complement modulate interactions between innate immune cells and the vascular endothelium are summarized as a basis for understanding the pathogenesis of different types of graft destruction.
ER  - 

TY  - JOUR
AU  - Tammaro, Antonella
AU  - Chello, Camilla
AU  - Sernicola, Alvise
AU  - Lampitelli, Salvatore
AU  - Cassiani, Flaminia
AU  - Liverani, Maria E.
TI  - Ecthyma gangrenosum in a 7-year-old girl: Is it a sign of acute lymphoblastic leukaemia?
JO  - International Wound Journal
JA  - Int Wound J
VL  - 16
IS  - 6
SN  - 9781118870143
UR  - https://doi.org/10.1111/iwj.13217
DO  - doi:10.1111/iwj.13217
SP  - 1575
EP  - 1576
PY  - 2019
ER  - 

TY  - JOUR
TI  - 21st Annual Meeting of the European Tissue Repair Society
JO  - Wound Repair and Regeneration
JA  - Wound Repair Regen
VL  - 19
IS  - 5
SN  - 9781118870143
UR  - https://doi.org/10.1111/j.1524-475X.2011.00728.x
DO  - doi:10.1111/j.1524-475X.2011.00728.x
SP  - A70
EP  - A97
PY  - 2011
ER  - 

TY  - JOUR
TI  - Poster Presentations
JO  - Mycoses
JA  - Mycoses
VL  - 58
IS  - S4
SN  - 9781118870143
UR  - https://doi.org/10.1111/myc.12380
DO  - doi:10.1111/myc.12380
SP  - 51
EP  - 226
PY  - 2015
ER  - 
